Korean drug maker Celltrion Healthcare recently presented new findings from a 2-part study at the Annual European Congress of Rheumatology 2019 meeting about subcutaneous biosimilar CT-P13 (Inflectra, Remsima).
All News
Advertisement
A recently published commentary examined issues surrounding biosimilars in the treatment of multiple sclerosis from an international point of view, noting the tremendous opportunity for cost savings while wondering if patient concerns are being adequately considered.
Advertisement
The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).
Advertisement
Advertisement
Trending on AJMC
1
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
2
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
3
First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA
4
5 Notable Oncology FDA Approvals Granted in May
5